Rifamycin MMX Shows Minimal Impact on Gut Resistome in Cirrhosis, Trends Towards Reduced Vancomycin Resistance
What the Researchers Tested
This study utilized shotgun metagenomic sequencing to analyze the gut resistome in patients with compensated cirrhosis. Participants were randomized into two groups: 15 received rifamycin SV MMX (RiVM) and 15 received placebo for 30 days. Gut microbial DNA was extracted from stool samples collected before and after the treatment period. The sequencing data was then processed to identify and quantify antibiotic resistance genes using the Comprehensive Antibiotic Resistance Database (CARD) for annotation. The research employed a combination of univariable and multivariable statistical methods, including LEfSe, paired-Wilcoxon testing, and MaAsLin3, to assess longitudinal changes in the resistome. Machine learning (ML) models were also deployed to evaluate ARG changes at both individual subject and group levels, aiming to discern subtle shifts that traditional statistical methods might overlook. The primary objective was to determine if RiVM, a rifamycin derivative, contributes to the expansion of ARGs, a concern previously raised by preclinical data regarding rifaximin.
What the Study Found
Rifamycin SV MMX (RiVM) induced minimal perturbation of the gut resistome, with no significant increase in antibiotic resistance genes (ARGs) observed after 30 days of therapy compared to placebo following FDR adjustment.
Univariable and multivariable analyses identified a trend towards lower vancomycin resistance-associated ARGs, specifically vanW and vanT operon-associated genes, after RiVM exposure.
Nominal increases in several Enterobacteriaceae-associated multidrug efflux regulators (e.g., evgS, emrK, mdtA) were noted post-rifamycin, but these did not maintain statistical significance after FDR correction.
Group-level machine learning models showed limited discrimination between RiVM and placebo groups for overall ARG changes, although within-subject longitudinal models demonstrated improved classification performance.
No increase in infections or treatment-related safety concerns were observed in the RiVM group during the 30-day trial period.
Why This Matters to Clinical Practice
The proliferation of antibiotic resistance genes (ARGs) in the gut microbiome is a critical concern in patients with liver cirrhosis, as it is associated with increased morbidity, higher rates of hospitalization, and poorer clinical outcomes. Patients with cirrhosis frequently require antibiotic courses, making them particularly vulnerable to resistome changes. Understanding the impact of commonly used medications, such as rifamycins for hepatic encephalopathy, on the gut resistome is therefore paramount for guiding clinical practice and mitigating the global challenge of antimicrobial resistance. This study provides crucial evidence suggesting that rifamycin MMX, over a 30-day course, does not significantly contribute to the expansion of gut ARGs in compensated cirrhosis. This finding is reassuring for clinicians who rely on rifamycins for managing complications of cirrhosis, as it alleviates concerns about exacerbating antibiotic resistance. The observed trend towards reduced vancomycin resistance, if validated in larger cohorts, could represent a significant clinical advantage, offering a potential strategy to modulate the resistome positively in a high-risk population.
Clinical & Workflow Takeaways
For practicing hepatologists and gastroenterologists managing patients with compensated cirrhosis, these findings are largely reassuring. The data suggest that the 30-day use of rifamycin SV MMX for indications such as hepatic encephalopathy is unlikely to significantly exacerbate the gut resistome, a critical consideration given the high burden of infection and antibiotic use in this population. Clinicians should continue to use rifamycin MMX as per established guidelines, with reduced concern regarding its contribution to overall ARG expansion. Furthermore, the intriguing signal of reduced vancomycin resistance warrants further investigation in larger, longer-term studies, as this could potentially lead to strategies for resistome modulation. However, vigilance for any potential shifts in specific resistance gene profiles, even those not reaching statistical significance in this small trial, remains prudent.
Limitations and What Remains Uncertain
The primary limitation of this study is its small sample size (n=30) and relatively short duration (30 days) of intervention, which may limit the generalizability and power to detect subtle or long-term changes in the gut resistome. While the study was double-blind and placebo-controlled, the small cohort may not fully represent the heterogeneity of patients with compensated cirrhosis. The observed 'trends' towards reduced vancomycin resistance and nominal increases in certain efflux regulators did not withstand FDR adjustment, indicating they should be interpreted with caution and require confirmation in larger, adequately powered trials. The study also focused on compensated cirrhosis, and its findings may not be directly applicable to patients with decompensated disease, who often have more profound gut dysbiosis and a higher risk of infection and antibiotic exposure. Future research should also explore the functional implications of these resistome changes on actual clinical outcomes, such as rates of infection with resistant organisms.
Explore the Work Behind Clinical AI
MedXchange Research Fellowship
Publish Clinical AI Research With Us
Our 10-week fellowship mentors physicians and researchers to build foundation models, analyze multimodal health datasets, and co-author peer-reviewed clinical studies.
Related Clinical AI Stories
AI Chatbot Performance in Orthopedic Education: GPT-4o Outperforms AAOS Members in Adult Reconstruction
A recent study published in the Rhode Island Medical Journal evaluated the performance of seven contemporary AI chatbots on 55 multiple-choice questions from the AAOS ResStudy question bank, focusing on adult reconstruction. The objective was to assess the accuracy, response time, and citation reliability of these AI models when confronted with clinically oriented orthopedic questions. Overall, the chatbots achieved a moderate accuracy of 67.5%, with significant variability among models and question types. Notably, GPT-4o demonstrated the highest accuracy at 80%, surpassing the average performance of AAOS members, who scored 75% on the same questions. Co-Pilot secured the second-best performance at 70.9%. The study meticulously categorized questions by anatomic region, concept (clinical presentation, prognosis, management), and AAOS-defined difficulty, revealing that AI chatbots excelled in descriptive knowledge (Clinical Presentation) but struggled with complex applied reasoning, such as prognosis and management. The findings suggest a valuable supplementary role for AI in orthopedic education, while highlighting areas needing further development.
AI in Precision Psychiatry: Navigating Biomarker Discovery from Concept to Clinic
The field of psychiatric biomarker discovery has long been hampered by challenges including suboptimal phenotypic characterization and limited cohort sizes. Recent advancements in artificial intelligence (AI), particularly large language models (LLMs) and self-supervised learning, are poised to revolutionize this landscape by transforming vast amounts of unstructured clinical text into quantifiable data and extracting insights from routinely collected, unlabeled psychiatric signals. This review highlights AI's role in the early stages of biomarker identification, from molecular interpretation to candidate generation. While AI demonstrates significant potential in identifying novel psychiatric biomarkers, a critical gap remains between computational discovery and clinical utility. The review emphasizes an inherent asymmetry: AI can rapidly generate biomarker candidates, but the rigorous, costly process of clinical validation for real-world application remains largely unaddressed by AI itself. The authors propose a structured, six-stage framework to bridge this gap, delineating the journey from intended clinical use and measurement validity to model evaluation, comparative utility, and ultimately, monitored deployment. This framework clarifies where AI can accelerate discovery and where traditional clinical validation is indispensable.
AI and Digital Technologies Transforming Multiple Sclerosis Neurorehabilitation
Recent advancements in neurorehabilitation for Multiple Sclerosis (MS) are shifting towards earlier, personalized, and technology-supported interventions. While pharmacological treatments have evolved, a significant number of individuals with MS (pwMS) continue to face complex symptom burdens, functional limitations, and reduced quality of life. This review emphasizes the integration of routine, multidimensional screening that extends beyond symptom severity to include functional status, participation restrictions, and social determinants of health (SDoH). The embrace of digital health technologies, such as wearables, remote monitoring, and AI-assisted assessments, offers new avenues for more ecologically valid and accessible evaluation of pwMS. The emerging paradigm posits neurorehabilitation as a fundamental component of comprehensive MS care, advocated for initiation early in the disease course rather than as a late-stage intervention. Exercise programs, cognitive rehabilitation, psychological therapies, and vocational rehabilitation are showing benefits across physical, cognitive, emotional, and fatigue domains, ultimately improving quality of life. Telerehabilitation and technology-supported approaches like virtual reality (VR), exergaming, and neuromodulation are proving instrumental in enhancing access to care and improving patient outcomes, despite ongoing needs for further research into their optimal application and widespread implementation.